Skip to main content
. 2013 Oct 8;15(5):R94. doi: 10.1186/bcr3496

Table 1.

Neoadjuvant systemic treatment regimens

Treatment regimen n
4 × epirubicin/cyclophosphamide (90/600 mg/m2 q21d)
 37
4 × epirubicin/cyclophosphamide (90/600 mg/m2 q21d) followed by 4 × docetaxel (175 mg/m2 q21d)
 256
4 × epirubicin/cyclophosphamide (90/600 mg/m2 q21d) followed by 4 × docetaxel (175 mg/m2 q21d) + 4 × Herceptin (6 mg/kg q21d)a
 26
4 × epirubicin/cyclophosphamide (90/600 mg/m2 q21d) followed by 12 × paclitaxel (80 mg/m2 weekly)
 7
4 × epirubicin/docetaxel (60/75 mg/m2 q21d)
 25
6 × doxorubicin/cyclophosphamide/docetaxel (50/500/75 mg/m2 q21d)
 29
6 × gemcitabine d1 + 8/epirubicin d1/docetaxel d1 (800/90/75 mg/m2 q21d) 20

aLoading dose: 8 mg/kg.